<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39439977</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2719-4523</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Rheumatology and immunology research</Title><ISOAbbreviation>Rheumatol Immunol Res</ISOAbbreviation></Journal><ArticleTitle>MIP-C: A new autoimmune rheumatic disease concomitant with the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>133</StartPage><EndPage>135</EndPage><MedlinePgn>133-135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2478/rir-2024-0018</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brion</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Mia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Environmental Science, Management, and Policy, University of California Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Cava</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicina Molecolare e Biotecnologie Mediche, Federico II University of Naples, Naples Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Immunol Res</MedlineTA><NlmUniqueID>9918419176206676</NlmUniqueID><ISSNLinking>2719-4523</ISSNLinking></MedlineJournalInfo><CoiStatement>Conflict of interest Antonio La Cava is a Co-Editor-in-Chief of the journal. The article was subjected to the standard procedures of the journal, with a review process independent of the editor and his research group.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39439977</ArticleId><ArticleId IdType="pmc">PMC11492818</ArticleId><ArticleId IdType="doi">10.2478/rir-2024-0018</ArticleId><ArticleId IdType="pii">rir-2024-0018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu X, Peng Q, Wang G.. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024;20:48. –.</Citation><ArticleIdList><ArticleId IdType="pubmed">38057474</ArticleId></ArticleIdList></Reference><Reference><Citation>Toquet S, Granger B, Uzunhan Y. The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. Autoimmun Rev. 2021;20:102788. et al.</Citation><ArticleIdList><ArticleId IdType="pubmed">33609802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Du G, Zhang G. Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. Ann Rheum Dis. 2022;81:e192. et al.</Citation><ArticleIdList><ArticleId IdType="pubmed">32759260</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassetti C, Borrelli C, Mazuy M. The relationship between infectious agents and juvenile dermatomyositis: a narrative update from the pediatric perspective. Front Immunol. 2024;15:1377952. et al.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11039888</ArticleId><ArticleId IdType="pubmed">38660309</ArticleId></ArticleIdList></Reference><Reference><Citation>Costin C, Morgan G, Khojah A. Lower NK cell numbers in children with untreated juvenile dermatomyositis during the COVID-19 pandemic. Clin Immunol Commun. 2023;3:42. et al. –.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9938532</ArticleId><ArticleId IdType="pubmed">38014397</ArticleId></ArticleIdList></Reference><Reference><Citation>David P, Sinh S, Iqbal K. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C) eBioMedicine. 2024:105136. et al.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11090026</ArticleId><ArticleId IdType="pubmed">38723554</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari S, Zickuhr L, Baral MR. A review of MDA-5 dermatomyositis and associated interstitial lung disease. Rheumato. 2024;4:33. et al. –.</Citation></Reference><Reference><Citation>Nombel A, Fabien N, Coutant F.. Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol. 2021;12:773352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564476</ArticleId><ArticleId IdType="pubmed">34745149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Yang Z, Pan T. SARS-CoV-2 Nsp8 suppresses MDA5 antiviral immune responses by impairing TRIM4-mediated K63-linked polyubiquitination. PLoS Pathog. 2023;19:e1011792. et al.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10681309</ArticleId><ArticleId IdType="pubmed">37956198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Wang Q, Wang Y. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol. 2021;12:791348. et al.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8720853</ArticleId><ArticleId IdType="pubmed">34987516</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>